Home » Interviews » INTERVIEW: Deltex Medical Group plc Well positioned for H2 and 2019
Deltex Medical Group PLC

INTERVIEW: Deltex Medical Group plc Well positioned for H2 and 2019

Deltex Medical Group Plc (LON:DEMG) CEO Andy Mears talks to DirectorsTalk about its interim results for the six months period ended 30 June 2018. Andy talks us through the highlights of the results, how he has settled into his role as CEO and the plans for the group operationally in the shorter and long term.

Deltex Medical Group plc manufactures and markets haemodynamic monitoring technologies. Deltex Medical’s proprietary ODM (TrueVueTM Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVueTM Doppler, which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical’s TrueVueTM System on the CardioQ-ODM+ monitor platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography (TrueVueTM Impedance) is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis
(TrueVueTM Pressurewave) uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.